Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutical…
FAIL · Does not pass the screen
10.84 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 7 days ago
Screened 2026-10-23 · the tape above runs as of 18:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price10.84 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.00)
Last reviewed23 Oct 2026 (7 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 10.84 against the desk's fair-value range, base estimate 21.68, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.00, read 2026-10-28
Ethical does not pass the values gate
Price10.84 USD
Fair value21.68
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown12.13-10.6% to today ✓Distribution gives way to Markdown after a 15% slide in 5 weeks
2026-08-31Read Distribution14.32-24.3% to today ✓Markup gives way to Distribution after a 42% slide in 4 weeks
2026-07-31Read Markup24.56-55.9% to today Accumulation gives way to Markup after a 35% rise in 4 weeks
2026-07-02Read Accumulation18.24-40.6% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Monte Rosa Therapeutics, Inc. holds its Markdown at $10.84. Consolidating, no directional conviction, held for 37 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 37 days
Price at the screen
$10.84
Valuation
N/A trailing · -5.07 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.37
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
8.74%
Below 33%
Interest-bearing debt is just 8.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
55.10%
Below 33%
Interest-bearing cash and securities are 55.1% of assets, above the one-third limit.
Fail
Receivables
31.53%
Below 49%
Money owed to the company is 31.5% of assets, under the 49% limit.
Pass
Revenue purity
10.46%
Below 5%
10.5% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Monte Rosa Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 55% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when GLUE's ethical verdict changes
Today GLUE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 7 covering, consensus Strong Buy. The average target sits +149% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech Dreams Meet Revenue Shrinking Fast
Turning the body's own protein cleanup system into a medicine sounds neat on paper. Monte Rosa is still at the trial stage with no profits yet, and its revenue has dropped 95 percent while the return on equity sits at minus 33 percent. Even with a fair value gap on the page and a clean ethical screen, the opportunity rating stays at none because the core numbers show a business that is burning cash rather than building it.
Analysts may cluster around a 33 dollar target, yet forward earnings sit at a negative 13.5 times and margins remain at zero. That combination leaves little room for error in a field where most candidates never reach the market. The gap between hope and cash flow is wide, and the market has priced it accordingly.
Risks centre on clinical failure and dilution that often follows for loss-making biotechs. Currency or macro moves matter less here than whether the next trial data actually moves the needle. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GLUE trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-30Markdown$10.84+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 223%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (6 analysts) rates it none, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markdown$10.84+9.6%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 9.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 223%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (6 analysts) rates it none, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$9.89+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 223%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (6 analysts) rates it none, with a mean price target of $32. Insiders have been net sellers over the past quarter.
2026-10-21Markdown$9.89-4.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 223%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (6 analysts) rates it none, with a mean price target of $32. Insiders have been net sellers over the past quarter.
2026-10-14Markdown$10.30-15.1%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 223%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (6 analysts) rates it none, with a mean price target of $32. Insiders have been net sellers over the past quarter.
2026-10-02Markdown · changed$12.13-15.3%Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 223%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (6 analysts) rates it none, with a mean price target of $32.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 41.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 223%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (6 analysts) rates it none, with a mean price target of $32.
2026-07-31Markup · changed$24.56+34.7%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 34.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 223%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (6 analysts) rates it none, with a mean price target of $32.
2026-07-18Accumulation$18.24+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 31% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 223%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (6 analysts) rates it none, with a mean price target of $32.
2026-07-03Accumulation$18.24+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
